How The Akebia Therapeutics (AKBA) Narrative Is Shifting After Vafseo Revenue And Protocol Updates [Yahoo! Finance]
Akebia Therapeutics, Inc. (AKBA)
Last akebia therapeutics, inc. earnings: 3/10 07:49 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.akebia.com/investor-relations
Company Research
Source: Yahoo! Finance
Akebia Therapeutics' fair value target is held at US$4.40 per share, with the latest model keeping this figure steady versus the prior view. That lack of movement comes even as analysts debate the impact of Q4 Vafseo revenue, protocol driven inventory reductions of about US$4.5m to US$5.0m, and what lower than expected sales mean for near term expectations. Read on to see how to track these shifting opinions and what to watch as the Akebia narrative continues to evolve. Stay updated as the Fair Value for Akebia Therapeutics shifts by adding it to your watchlist or portfolio . Alternatively, explore our Community to discover new perspectives on Akebia Therapeutics. What Wall Street Has Been Saying ?? Bullish Takeaways BTIG keeps a Buy rating on Akebia even after trimming its price target to US$4 from US$5, signaling that the firm still sees upside potential from current levels. BTIG highlights the impact of a new US Renal Care protocol that led to an estimated US$4.5m to US$
Show less
Read more
Impact Snapshot
Event Time:
AKBA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AKBA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AKBA alerts
High impacting Akebia Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
AKBA
News
- Akebia Therapeutics, Inc. (AKBA) Discusses Pipeline Progress and Strategic Focus on Kidney Disease Treatments at R&D Day Transcript [Seeking Alpha]Seeking Alpha
- Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- Akebia Therapeutics R&D Day: Vafseo Growth Plan, Praliciguat Phase 2, New Kidney Pipeline Targets [Yahoo! Finance]Yahoo! Finance
- Akebia Therapeutics Appoints Biopharmaceutical Leader Philip Vickers, Ph.D. to its Board of DirectorsGlobeNewswire
- Is Akebia Therapeutics (AKBA) One of the Best Penny Stocks to Buy [Yahoo! Finance]Yahoo! Finance
AKBA
Earnings
- 2/26/26 - Miss
AKBA
Sec Filings
- 4/3/26 - Form 4
- 4/3/26 - Form 3
- 4/1/26 - Form 8-K
- AKBA's page on the SEC website